Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.
Type:
Grant
Filed:
May 5, 2011
Date of Patent:
June 2, 2015
Assignee:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Janis, Riika Katainen, Kirill Tarasov
Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.
Type:
Application
Filed:
April 8, 2011
Publication date:
January 30, 2014
Applicant:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Janis, Riikka Katainen, Kirill Tarasov
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Type:
Application
Filed:
June 20, 2011
Publication date:
August 22, 2013
Applicant:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.
Type:
Application
Filed:
May 5, 2011
Publication date:
February 21, 2013
Applicant:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Janis, Riika Katainen, Kirill Tarasov
Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.
Type:
Application
Filed:
December 21, 2011
Publication date:
October 11, 2012
Applicant:
Zora Biosciences Oy
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
Abstract: The invention concerns a method for diagnosing a child's susceptibility for developing type 1 diabetes by using a serum metabolite as biomarker. The invention concerns also a method for prevention of the onset of type 1 diabetes in a child.
Type:
Application
Filed:
September 10, 2007
Publication date:
December 24, 2009
Applicant:
ZORA BIOSCIENCES OY
Inventors:
Matej Oresic, Olli Simell, Tuulikki Seppänen-Laakso, Marko Sysi-Aho
Abstract: This invention provides a diagnostic method for determining statin induced myopathy. The method is especially applicable for determining warnings, early signs and also symptomatic myopathy. The method includes collecting a lipidomic profile from a biological sample such as blood or serum and comparing the obtained lipidomic profile to reference lipidomic markers. The reference lipidomic markers have been established by combining a pro-inflammatory muscle tissue gene expression profile with a lipidomic profile associated with high dosage statin treatment. This invention also relates to a kit for performing a method for determining statin induced myopathy.
Type:
Grant
Filed:
June 12, 2007
Date of Patent:
November 3, 2009
Assignee:
Zora Biosciences Oy
Inventors:
Reijo Laaksonen, Matej Oresic, Terho Lehtimäki, Hannu Päivä